TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
IMUX

Immunic Inc

Healthcare · Biotechnology

7.50$ -3.7% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Immunic Inc (IMUX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 88.0% of the shares are freely tradable; institutional investors hold 46.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 46.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 1.0%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 88.0%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 16.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 14Mio.

Largest Shareholders

Institutions

Institutions IMUX
Name Stake (%) Shares Change (%) Date
Aberdeen Group PLC 6.04 824,393 +0.0 06/30/2026
Bvf Inc 5.61 765,295 +0.0 06/30/2026
Millennium Management LLC 5.43 740,347 +95.9 06/30/2026
Avidity Partners Management LP 4.91 669,941 +900.0 06/30/2026
BRAIDWELL LP 4.73 645,010 +0.0 06/30/2026
LAURION CAPITAL MANAGEMENT LP 4.47 610,326 +57.2 06/30/2026
Vanguard Capital Management, LLC 4.19 571,561 +11.2 06/30/2026
Jones Hill Capital LP 3.96 539,814 +0.0 06/30/2026
Nantahala Capital Management, LLC 3.67 501,292 +100.0 06/30/2026

Funds

Funds IMUX
Name Stake (%) Shares Change (%) Date
abrdn Healthcare Investors 3.47 473,877 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?